Risk for second bladder and rectal malignancies from cervical cancer irradiation.


Journal

Journal of applied clinical medical physics
ISSN: 1526-9914
Titre abrégé: J Appl Clin Med Phys
Pays: United States
ID NLM: 101089176

Informations de publication

Date de publication:
Jul 2021
Historique:
revised: 17 04 2021
received: 27 01 2021
accepted: 19 04 2021
pubmed: 23 5 2021
medline: 24 7 2021
entrez: 22 5 2021
Statut: ppublish

Résumé

The objective of this study was to estimate the risk of developing second malignancies to partially in-field organs from volumetric modulated arc therapy (VMAT) of cervical cancer and to compare the above risks with those from the conventional three-dimensional conformal radiotherapy (3D-CRT). Seventeen consecutive patients with uterine cervix carcinoma were selected. VMAT and 3D-CRT plans were generated with 6 and 10 MV photons, respectively. The prescribed tumor dose was 45 Gy given in 25 fractions. Differential dose-volume histogram data from the treatment plans were obtained for the partially in-field organs such as bladder and rectum. These data were used to estimate the patient-specific lifetime attributable risk (LAR) for bladder and rectal cancer induction with a non-linear model based on a mixture of plateau and bell-shaped dose-response relationships. The estimated risks per 10000 people were compared with the baseline risks for unexposed population. The patient-specific rectal cancer risk estimates from VMAT were significantly lower than those from 3D-CRT (P = 0.0144). The LARs for developing bladder malignancies from VMAT were significantly high compared to those from conventional irradiation (P = 0.0003). The mean difference between the patient-specific LARs for radiation-induced bladder and rectal malignancies as derived from 3D-CRT and VMAT plans was 6.6% and 2.0%, respectively. The average LAR for developing bladder and rectal malignant diseases due to VMAT was 9.2 × 10

Identifiants

pubmed: 34021692
doi: 10.1002/acm2.13274
pmc: PMC8292701
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103-109

Informations de copyright

© 2021 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine.

Références

Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
Phys Med. 2017 Oct;42:232-238
pubmed: 28242139
Natl Vital Stat Rep. 2019 Jun;68(7):1-66
pubmed: 32501200
Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):539-45
pubmed: 19427555
Theor Biol Med Model. 2011 Jul 26;8:27
pubmed: 21791103
Med Phys. 2016 Apr;43(4):1841
pubmed: 27036581
Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1204-16
pubmed: 15990026
Med Phys. 2017 Oct;44(10):e391-e429
pubmed: 28688159
Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):e23-8
pubmed: 22543211
Radiother Oncol. 2018 Jun;127(3):404-416
pubmed: 29728273
Radiat Oncol. 2011 Jun 08;6:67
pubmed: 21651799
J Appl Clin Med Phys. 2020 Dec;21(12):197-205
pubmed: 33147377
J Appl Clin Med Phys. 2020 Sep;21(9):82-89
pubmed: 32671989
Onco Targets Ther. 2018 Oct 18;11:7179-7186
pubmed: 30425510
J Appl Clin Med Phys. 2018 Sep;19(5):609-615
pubmed: 30058257
Phys Med Biol. 2010 Dec 7;55(23):7009-23
pubmed: 21076193
J Natl Cancer Inst. 1985 May;74(5):955-75
pubmed: 3858584
Radiat Oncol. 2014 Feb 21;9:61
pubmed: 24555547
Strahlenther Onkol. 2010 Mar;186(3):174-9
pubmed: 20339826
Med Phys. 2018 May;45(5):e84-e99
pubmed: 29468678
Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):428-34
pubmed: 18037584
Radiat Prot Dosimetry. 2018 Dec 1;182(2):208-214
pubmed: 29608744
Phys Med. 2017 Oct;42:285-291
pubmed: 28189418
Radiother Oncol. 2008 Nov;89(2):180-91
pubmed: 18692929
Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):1-7
pubmed: 16618572
J Natl Cancer Inst. 2007 Nov 7;99(21):1634-43
pubmed: 17971527
Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):83-8
pubmed: 12694826
Strahlenther Onkol. 2002 Jul;178(7):357-62
pubmed: 12163989
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
J Clin Oncol. 2018 Aug 20;36(24):2538-2544
pubmed: 29989857
Phys Med Biol. 2015 Feb 7;60(3):1237-57
pubmed: 25590229

Auteurs

Michalis Mazonakis (M)

Department of Medical Physics, Faculty of Medicine, University of Crete, Crete, Greece.

Efrosyni Lyraraki (E)

Department of Radiotherapy and Oncology, University Hospital of Iraklion, Iraklion, Crete, Greece.

Maria Tolia (M)

Department of Radiotherapy and Oncology, University Hospital of Iraklion, Iraklion, Crete, Greece.

John Damilakis (J)

Department of Medical Physics, Faculty of Medicine, University of Crete, Crete, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH